Research ArticleArticle
Five Potentially Modifiable Factors Predict Poor Quality of Life in Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis
Linda E. Dean, Gary J. Macfarlane and Gareth T. Jones
The Journal of Rheumatology August 2017, jrheum.160411; DOI: https://doi.org/10.3899/jrheum.160411
Linda E. Dean
From the Epidemiology Group, University of Aberdeen; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK. GTJ has received research funding from AbbVie, Pfizer, and UCB. GJM has received research funding from AbbVie, Pfizer, and UCB in the form of unrestricted or investigator initiated grants. GJM also chairs a Pfizer research grant panel, for which he receives an honorarium. LED conducted the analysis while funded by an MRC PhD studentship. L.E. Dean, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.J. Macfarlane, MD (Hons), Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.T. Jones, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen. Address correspondence to Dr. G.T. Jones, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail: gareth.jones@abdn.ac.uk. Accepted for publication May 13, 2017.
Gary J. Macfarlane
From the Epidemiology Group, University of Aberdeen; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK. GTJ has received research funding from AbbVie, Pfizer, and UCB. GJM has received research funding from AbbVie, Pfizer, and UCB in the form of unrestricted or investigator initiated grants. GJM also chairs a Pfizer research grant panel, for which he receives an honorarium. LED conducted the analysis while funded by an MRC PhD studentship. L.E. Dean, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.J. Macfarlane, MD (Hons), Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.T. Jones, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen. Address correspondence to Dr. G.T. Jones, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail: gareth.jones@abdn.ac.uk. Accepted for publication May 13, 2017.
Gareth T. Jones
From the Epidemiology Group, University of Aberdeen; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK. GTJ has received research funding from AbbVie, Pfizer, and UCB. GJM has received research funding from AbbVie, Pfizer, and UCB in the form of unrestricted or investigator initiated grants. GJM also chairs a Pfizer research grant panel, for which he receives an honorarium. LED conducted the analysis while funded by an MRC PhD studentship. L.E. Dean, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.J. Macfarlane, MD (Hons), Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.T. Jones, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen. Address correspondence to Dr. G.T. Jones, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail: gareth.jones@abdn.ac.uk. Accepted for publication May 13, 2017.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Five Potentially Modifiable Factors Predict Poor Quality of Life in Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis
Linda E. Dean, Gary J. Macfarlane, Gareth T. Jones
The Journal of Rheumatology Aug 2017, jrheum.160411; DOI: 10.3899/jrheum.160411